Related Experiment Video
Updated: Jan 7, 2026
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies
Prakhar Srivastava1, Elizabeth Singleton2, Taylor Morrisette2,3
1P3 Research Laboratory, Division of Pharmaceutics and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH, USA.
Abstract:
Methicillin-susceptible Staphylococcus aureus (MSSA) remains a major cause of morbidity and mortality worldwide, particularly owing to its role in complicated infections including bloodstream infections, osteomyelitis, and infective endocarditis. In 2017, an estimated 119,247 cases of S. aureus bloodstream infections were reported in the USA, resulting in approximately 19,832 deaths. While the prevalence of MSSA varies by region and demographic factors, MSSA has been reported to be approximately two times more common than methicillin-resistant S. aureus (MRSA) in both total and complicated infections. Cefazolin, a first-generation cephalosporin, is widely used for MSSA treatment owing to its favorable safety profile, cost-effectiveness, and availability. However, its efficacy may be compromised by the cefazolin inoculum effect (CzIE)-a phenomenon where cefazolin activity diminishes at high bacterial densities, such as those found in endocardial vegetations or abscesses. Importantly, CzIE is not universally present across all MSSA isolates and geographical areas, with reported prevalence ranging from 0% to 55%. Initially considered a result of producing specific allotypes of the staphylococcal β-lactamase enzyme BlaZ (i.e., allotypes A and C), recent work sheds new light on different BlaZ allotypes associated with the effect while establishing that no single genetic determinant or allotype is uniquely and definitively responsible. When present, CzIE can lead to elevated cefazolin MICs at high inocula, potentially resulting in treatment failure, prolonged hospitalization, and increased mortality. Despite these concerns, clinical data remain inconclusive, and the true impact of CzIE on patient outcomes is still under investigation. This review critically evaluates the molecular basis, clinical relevance, and diagnostic challenges of CzIE, with the goal of informing antibiotic stewardship and optimizing treatment strategies for serious MSSA infections.
Insights
Methicillin-susceptible Staphylococcus aureus (MSSA) infections are common. The cefazolin inoculum effect (CzIE) can reduce cefazolin effectiveness against MSSA, potentially impacting treatment outcomes.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Methicillin-susceptible Staphylococcus aureus (MSSA) causes significant global morbidity and mortality.
- MSSA infections, including bloodstream infections, osteomyelitis, and endocarditis, are more prevalent than methicillin-resistant S. aureus (MRSA).
- Cefazolin is a primary treatment for MSSA due to its safety and cost-effectiveness.
Purpose of the Study:
- To review the molecular basis, clinical relevance, and diagnostic challenges of the cefazolin inoculum effect (CzIE).
- To inform antibiotic stewardship and optimize treatment strategies for serious MSSA infections.
Main Methods:
- Literature review evaluating molecular mechanisms of CzIE.
- Analysis of clinical data and reported prevalence of CzIE.
- Discussion of diagnostic challenges and impact on treatment.
Main Results:
- The cefazolin inoculum effect (CzIE) diminishes cefazolin activity at high bacterial densities.
- CzIE prevalence varies geographically (0-55%) and is not linked to a single genetic determinant.
- Elevated cefazolin minimum inhibitory concentrations (MICs) due to CzIE may lead to treatment failure.
Conclusions:
- CzIE poses a challenge to effective MSSA treatment, potentially increasing mortality.
- Further clinical investigation is needed to fully understand the impact of CzIE on patient outcomes.
- Optimizing diagnostic approaches and treatment strategies for CzIE is crucial for managing serious MSSA infections.
